CJC-1295safety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for CJC-1295 as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. CJC-1295 is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

Clinical-trial safety data for CJC-1295 derive principally from the Teichman 2006 publication and subsequent Phase II HIV-lipodystrophy work, providing a moderate-size human safety dataset for the DAC variant. The reported adverse-event profile was generally mild: injection-site reactions (erythema, pruritus, transient nodules) were the most common; mild flushing and brief somnolence following injection were reported; no clinically significant changes in routine haematology, biochemistry, or vital signs were observed at therapeutic dose ranges. No serious adverse events attributable to CJC-1295 itself were reported in the published trials. The principal theoretical concerns relate to chronic dosing — sustained GH/IGF-1 elevation rather than the peptide's acute effects. Chronic supraphysiological IGF-1 elevation theoretically carries oncogenic risk through IGF-1R activation on susceptible tissues, with epidemiological associations between elevated IGF-1 and several cancer types (prostate, breast, colorectal). The Teichman dataset showed IGF-1 elevations within the upper physiological range rather than supraphysiological, but extended chronic dosing data are absent. Insulin resistance is a well-documented complication of chronic GH/IGF-1 elevation, with fasting glucose and HOMA-IR shifting unfavourably during sustained GH replacement; pulsatile-pattern dosing (no-DAC variant or sermorelin-style protocols) mitigates this risk. The DAC variant's sustained receptor occupancy raises concerns specific to non-pulsatile GH delivery: GH receptor downregulation, loss of IGF-1 sensitivity over time, and the metabolic phenotype of chronic acromegaly-like exposure. These are theoretical rather than documented in the published trials, but they constitute the principal reason much research-community use favours the no-DAC variant despite its less convenient dosing. No serious immediate adverse events have been documented for either variant at research-protocol doses. Acute hypotension or anaphylaxis have not been reported. The peptide is sufficiently large (3,367 or 3,647 Da) that immunogenicity is theoretically possible with repeated dosing; mild ELISA-detectable anti-drug antibodies have been described in research-grade preparations but have not produced documented loss of efficacy. Sterility and endotoxin content of research-chemical-grade material remain the dominant practical safety variables, as with all injectable research peptides.

UK regulatory status

CJC-1295 (both DAC and no-DAC variants) is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. CJC-1295 is captured by the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth-hormone-releasing hormone analogue. Athletes subject to anti-doping testing should treat all GHRH-analogue and GHRP-class peptides as prohibited in-competition and out-of-competition regardless of claimed research purpose. WADA's approach to GH-axis peptides has hardened materially since approximately 2015 with the introduction of GH-isoform-ratio testing and IGF-1 elevation monitoring as detection tools alongside direct peptide identification. MHRA enforcement actions concerning CJC-1295 supply specifically have not been published in the public domain, but generic warnings on unlicensed peptide supply for human use apply. Research-grade CJC-1295 for legitimate in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. For animal research under ASPA (Animals (Scientific Procedures) Act 1986), CJC-1295 work in vertebrates requires Personal, Project, and Establishment Licences from the Home Office Drugs and Firearms Licensing Unit, and the work must pass a local Animal Welfare and Ethical Review Body assessment. The use of CJC-1295 in research animals does not automatically engage controlled-substance provisions but does require standard ASPA compliance.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. CJC-1295 is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full CJC-1295 research context including mechanism, study citations, and references, see the main CJC-1295 research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.